NEW YORK (360Dx) – SQI Diagnostics and Microdrop on Thursday announced an agreement to sell SQI's celiac and wheat allergy, and rheumatoid arthritis tests to the directly to consumers. 

Microdrop will license the rights to the two SQI microarray-based tests. The rights are subject to performance obligations by both parties, including a minimum number of kits to be purchased by Microdrop, they said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.